ABSTRACT: Prevention of cardiovascular disease, undoubtedly an emphasis of clinical care in 2014, will provide both opportunities and challenges to patients and their healthcare providers. The recently-released ACC/AHA guidelines on assessment of cardiovascular risk, lifestyle management to reduce cardiovascular risk, management of overweight and obesity, and treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk, have introduced new concepts and revised prior conventional strategies. New to risk assessment are the Pooled Cohort Equations, targeting the expanded concept of atherosclerotic cardiovascular disease (ASCVD) and focusing not solely on mortality but as well on major nonfatal events. The lifestyle management focuses on diet and physical activity for lipid and blood pressure control. The cholesterol guideline identifies four high-risk groups with the greatest benefits from statin therapy: preexisting ASCVD, primary LDL-C elevations ≥190 mm/dl, those 45-75 years with diabetes and LDL-C 70-189 mm/dl without clinical ASCVD, and those 40-75 years without clinical ASCVD with an LDL-C 70-189 mg/dl with a 7.5% or greater 10-year ASCVD risk. Eliminated are arbitrary LDL-C treatment targets, with individual patient risk status guiding who should take statins and the appropriate intensity of statin drugs. Patient-physician discussions of individual benefits and risks are paramount. Management of high blood pressure remains controversial, with two different expert panels offering varying treatment targets; there is general agreement on a <140/90 mmHg goal, but substantial disagreement on blood pressure targets for older adults. Clinicians and their patients deserve a well-researched concensus document.
INTRODUCTION
The year 2014 will likely focus substantially on cardiovascular risk assessment and preventive interventions, buttressed by requirements of the Affordable Care Act. 1 
Four recent and longawaited American College of Cardiology/American Heart Association (ACC/AHA) Guidelines provide the clinician with evidence-based recommendations for Assessment of Cardiovascular Risk,
2 Lifestyle Management to Reduce Cardiovascular Risk, 3 Management of Overweight and Obesity, 4 and Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk. 5 The 
. 7 These BP recommendations differ in targets and therapeutic approaches and will require reconciliation. Because cardiovascular disease (CVD) remains the leading cause of mortality in the United States, 8 Figure 1 . Applying classification of recommendation and level of evidence. *Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes, history of prior myocardial infarction, history of heart failure, and prior aspirin use. A recommendation with level of evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective. †For comparative effectiveness recommendations (class I and IIa, level of evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated. Reproduced with permission from Goff et 
and these guidelines substantially impact clinical practice and focus the needs of most patients, I have chosen to highlight the pivotal recommendations and provide a brief commentary for each. My commentaries are indicated in italics, accompanying my abstracted Guideline recommendations.

ASSESSMENT OF CARDIOVASCULAR RISK
Identifying Patients Who Need to Lose Weight
• Measure height and weight and calculate body mass index (BMI) at least annually (COR: I, LOE: C).
• Use current cut points for overweight (BMI >25.0-29.9 kg/m 2 ) and obesity (BMI ≥30 kg/m 2 ) to identify increased CVD risk. Use current cut point for obesity (BMI ≥30 kg/m 2 ) to identify increased risk of all-cause mortality (COR: I, LOE: B)
• The greater the BMI, the greater the risk of CVD, type 2 diabetes, and all-cause mortality (COR: I, LOE: B).
• Measure waist circumference at least annually in overweight and obese adults. The greater the waist circumference, the greater the risk of CVD, type 2 diabetes, and all-cause mortality (COR: IIa, LOE: B).
Matching Treatment Benefits With Risk Profiles: Effect of Weight Reduction on CVD Risk Factors, Events, Morbidity, and Mortality
meaningful health benefits. Greater weight loss produces greater benefit: meaningful reductions in triglycerides, blood glucose, hemoglobin A1C, and risk of developing type 2 diabetes. Greater weight loss further reduces BP, improves LDL-C and HDL-C, and reduces the need for medications to control BP, blood glucose, and lipids (COR: 1, LOE: A).
Diets for Weight Loss
Prescribe diet to reduce caloric intake as part of comprehensive lifestyle intervention using 1 of following:
• 1200 to 1500 kcal/d for women and 1500 to 1800 kcal/d for men.
• 500 kcal/d or 750 kcal/d energy deficit.
• Evidence-based diet that restricts certain food types (such as high-carbohydrate foods, low-fiber foods, or high-fat foods) to create energy deficit by reduced food intake (COR: I, LOE: A).
Prescribe calorie-restricted diet based on patient's preferences and health status and preferably refer to nutrition professional for counseling (COR: I, LOE: A).
Lifestyle Intervention and Counseling
• Advise participation for ≥6 months in comprehensive lifestyle program that assists adherence to lowercalorie diet and increased physical activity through behavioral strategies (COR: I, LOE: A).
• Prescribe on-site, high-intensity (ie, ≥14 sessions in 6 months) comprehensive weight loss interventions by trained interventionist (COR: I, LOE: A).
• Electronically delivered weight loss programs (including by telephone) that include personalized feedback may result in less weight loss than face-toface interventions (COR: IIa, LOE: A).
• Some commercially-based programs that provide comprehensive lifestyle intervention are an option for weight loss, if there is peer-reviewed published evidence of safety and efficacy (COR: IIa, LOE: A).
• Use very low-calorie diet (<800 kcal/day) only in limited circumstances provided by trained practitioners in a medical-care setting. Medical supervision is required because of rapid weight loss and potential for health complications (COR: IIa, LOE: A).
• Advise overweight and obese individuals who have lost weight to participate long term (≥1 year) in a comprehensive weight loss maintenance program (COR: I, LOE: A).
• For weight loss maintenance, prescribe face-to-face or telephone-delivered weight loss maintenance programs to help participants engage in high-level physical activity (ie, 200 to 300 min/wk), monitor body weight regularly (weekly or more frequently), and consume reduced-calorie diet (needed to maintain lower body weight) (COR: I, LOE: A). Major recommendations for statin therapy for ASCVD prevention are diagrammed in Figures 3 and 4 .
Treatment Targets
• No sufficient evidence was identified to support the continued use of fixed LDL-C and/or non-HDL-C treatment targets. No recommendations were provided for or against specific LDL-C or non-HDL-C targets for primary or secondary prevention of ASCVD.
Secondary Prevention
• Initiate or continue high-intensity statin as first-line therapy in women and men ≤75 years old with clinical ASCVD (COR: I, LOE: A) ( interactions, and to consider patient preferences in initiating or continuing moderate-or high-intensity statin use (COR: IIa, LOE: B).
Primary Prevention in Individuals ≥21 Years Old With LDL-C ≥190 mg/dL
• Evaluate individuals with LDL ≥190 mg/dL or triglycerides ≥500 mg/dL for secondary causes of hyperlipidemia (COR: I, LOE: B).
• Treat with statin regardless of estimated 10-year ASCVD risk. Use high-intensity statin or maximum tolerated statin if unable to tolerate high-intensity statin (COR: I, LOE: B).
• It is reasonable to intensify statin to achieve at least 50% LDL-C reduction (COR: IIa, LOE: B).
• After maximum intensity statin achieved, may consider addition of non-statin drug to further lower LDL-C (COR: IIb, LOE: C). 
Primary Prevention in Individuals Without Diabetes Mellitus and With LDL-C 70 to 189 mg/dL
• Use Pooled Cohort Equations to estimate 10-year ASCVD risk to guide initiation of statin (COR: 1, LOE: B).
• Treat adults 40 to 75 years old with estimated 10-year ASCVD risk ≥7.5% with moderate-to high-intensity statin (COR: I, LOE: A).
• Reasonable to offer treatment with moderate-intensity statin to adults 40 to 75 years old with LDL-C 70 to 189 mg/dL and without diabetes and estimated 10-year ASCVD risk of 5% to <7.5% (COR: IIa, LOE: B).
• Before initiating statin for primary prevention of ASCVD with LDL-C 70 to 189 mg/dL but no clinical ASCVD or diabetes mellitus, it is reasonable to discuss potential for ASCVD risk-reduction benefits and adverse effects, drug-drug interactions, and patient preferences (COR: IIa, LOE: C).
• In adults with LDL-C <190 mg/dL not identified in a statin benefit group, or for whom after quantitative risk assessment a treatment decision is uncertain, may consider additional factors to inform treatment decision making. May consider statin therapy for primary prevention only after evaluating potential for ASCVD risk reduction benefits, adverse effects, drugdrug interactions, and patient preferences (COR: IIb, LOE: C).
Heart Failure and Hemodialysis
• No recommendations for initiation or discontinuation of statins in patients with New York Heart Association class II-IV ischemic systolic heart failure or on maintenance hemodialysis because of insufficient information.
Recommendations further provide focused evidence-based responses to frequently asked questions about cholesterol lowering: safety of statin use, nonstatin safety, monitoring and optimizing statin therapy, and addressing insufficient response to statins. Nonstatin therapies were not considered to provide acceptable ASCVD risk-reduction benefit compared to their potential adverse effects in routine preventive care.
Summary: Statin Safety Recommendations
• To maximize statin safety, base the appropriate statin and dose on patient characteristics, level of ASCVD risk, and potential for adverse effects. Use moderate-intensity statin in individuals with characteristics predisposing to statin-associated adverse effects, in whom a high-intensity statin is otherwise recommended (COR: I, LOE: B).
• Multiple or serious comorbidities, including impaired renal or hepatic function.
• History of previous statin intolerance or muscle disorders.
• Unexplained alanine transferase (ALT) elevations >3 times upper limit of normal (ULN).
• Patient characteristics or concomitant use of drugs affecting statin metabolism.
• Patients >75 years of age.
May modify decisions for higher-intensity statin with history of hemorrhagic stroke and Asian ancestry.
• Do not routinely measure creatine kinase (CK) in individuals receiving statin (COR: III no benefit, LOE: A). 
Summary: Nonstatin Safety Recommendations
Safety of Niacin:
• Obtain baseline liver transaminases, fasting blood glucose or hemoglobin A1c, and uric acid before initiating niacin, during up-titration and every 6 months thereafter ((COR: I, LOE: B).
• Niacin should not be used if (COR III harm, LOE: B)
• Transaminase elevations are >2 to 3 times ULN.
• Persistent severe cutaneous symptoms, persistent hyperglycemia, acute gout, unexplained abdominal pain, or gastrointestinal symptoms occur.
• New-onset atrial fibrillation or weight loss occurs.
• Reconsider the potential for ASCVD benefits and adverse effects before reinitiating niacin with niacin adverse effects (COR: I, LOE: B).
• To reduce the frequency and severity of adverse cutaneous symptoms, reasonable to start niacin at a low dose and titrate to a higher dose, take niacin with food, or premedicate with aspirin to alleviate flushing (COR: IIa, LOE: C).
Safety of Bile Acid Sequestrants:
• Do not use bile acid sequestrants (BAS) with baseline fasting triglyceride ≥300 mg/dL or type II hyperlipoproteinemia, because severe triglyceride elevations might occur (COR: III harm, LOE: B).
• Reasonable to use BAS with caution if baseline triglyceride level is 250 to 299 mg/dL; evaluate fasting lipid panel in 4 to 6 weeks. Discontinue BAS if triglycerides exceed 400 mg/dL (COR: IIa, LOE: C).
Safety of Cholesterol-Absorption Inhibitors:
• Reasonable to obtain baseline hepatic transaminases before initiating ezetimibe. When ezetimibe coadministered with statin, monitor transaminase levels as clinically indicated and discontinue ezetimibe if persistent ALT elevations are >3 times ULN (COR: IIa, LOE B).
• May consider fenofibrate concomitantly with lowor moderate-intensity statin only if benefits from ASCVD risk reduction or triglyceride lowering when triglycerides >500 mg/dL outweigh potential for adverse effects (COR: IIb, LOE: C).
• Evaluate renal status before fenofibrate initiation, within 3 months after initiation, and every 6 months thereafter. Assess renal safety with both serum creatinine and estimated glomerular filtration rate (eGFR) based on creatinine (COR: I, LOE: B).
• 
Safety of Omega-3 Fatty Acids:
• If eicosapentaenoic acid and/or docosahexaenoic acid are used for management of severe hypertriglyceridemia (triglycerides ≥500 mg/dL), reasonable to evaluate patient for gastrointestinal disturbances, skin changes, and bleeding (COR: IIa, LOE: B).
Recommendations for Monitoring, Optimizing, and Insufficient Response to Statin Therapy
Monitoring Statin Therapy:
• Regularly assess adherence to medication and lifestyle, therapeutic response to statin and safety. Perform fasting lipid panel 4 to 12 weeks after initiation for dose adjustment and every 3 to 12 months thereafter along with other safety measures as clinically indicated (COR: I, LOE: A).
Optimizing Statin Therapy:
• Use maximum tolerated statin intensity in individuals for whom high-or moderate-intensity statin is advised but not tolerated (COR: I, LOE: B).
Insufficient Response to Statin Therapy:
• With less-than-desired therapeutic response or intolerance of recommended statin intensity, reinforce medication adherence, adherence to intensive lifestyle changes, and exclude secondary causes of hyperlipidemia (COR: I, LOE: A).
• Reasonable to use following as desirable therapeutic response to recommended statin intensity (COR: IIa, LOE: B):
• Approximately ≥50% LDL-C reduction with clinical ASCVD or LDL-C ≥190 mg/dL • Approximately 30% to 50% LDL-C reduction without clinical ASCVD or LDL-C 70 to 189 mg/dL • For most people, the BP goal is <140/<90 mm Hg.
• Lower targets may be appropriate for some populations with hypertension.
• Lifestyle modifications should be initiated in all patients ( Figure 5 ).
• Self-monitoring is encouraged for most patients.
• Suggested medications for treatment of hypertension in the presence of certain medical conditions include:
• Coronary artery disease/post-MI: β-blocker (BB), angiotensin-converting enzyme inhibitor (ACEI).
• Systolic heart failure: ACEI or angiotensin receptor blocker (ARB), BB, aldosterone antagonist, thiazide.
• Diastolic heart failure: ACEI or ARB, BB, thiazide. Table 2 ) and strength of recommendation (their Table 3 ) than was used in the previously reviewed guidelines (Figure 2) .
Nine specific recommendations are incorporated in a management algorithm (Figure 6 ): Figure  6 ). Adjust regimen until goal BP is reached; if it cannot be accomplished with 2 drugs, add and titrate third drug. Do not use ACEI and ARB together in same patient. If goal BP cannot be reached using only drugs in recommendation, an antihypertensive drug from other classes can be used. Consider referral to hypertension specialist if goal BP cannot be attained using above strategies (Expert Opinion, Grade E). 
